H.C. Wainwright lowered the firm’s price target on Applied DNA Sciences to $1.50 from $7 and keeps a Buy rating on the shares following the equity financing. The firm’s projected shares outstanding in 12 months have increased to 20.3M by the end of June 2025, which yields a value of $1.50 per share.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on APDN:
- Applied DNA announces notice of allowance for U.S. patent covering Linea RNAP
- Applied DNA Sciences’ $12M Securities Offering and Agreement
- Applied DNA Sciences downgraded to Hold from Buy at Maxim
- Applied DNA Sciences announces presentation on use of Linea DNA
- Applied DNA Sciences reports Q2 EPS ($5.31), two estimates ($4.50)